特应性皮炎疾病模型

疾病简介

特应性皮炎（atopic dermatitis, AD）是一种以皮肤持续性瘙痒为特征的慢性、复发性的炎症性皮肤病。它通常发生在儿童和青少年中，但也可能在成年人中出现。特应性皮炎的发病原因复杂，可能与遗传、环境、免疫等多种因素有关。

疾病模型

南模生物长期致力于自身免疫性疾病相关研究，利用奥沙唑酮（Oxazolone，OXA）和2,4-二硝基氟苯（2，4-dinitrofluorobenzene，DNFB）等开发了多种特应性皮炎小鼠模型，为相关药物的药效评估和安全性评价提供了强有力的工具。

OXA诱导的hIL4/hIL4R人源化小鼠AD模型及药效评价

image.png

Fig.1 OXA induced AD model in hIL4/hIL4R mice. (A) body weight (B) body weight change.

image.png

Fig.2 OXA induced AD model in hIL4/hIL4R mice. (A) gross observation on Day 21  (B) ear thickness (C) clinical score of skin.

image.png

Fig.3 OXA induced AD model in hIL4/hIL4R mice. (A) serum IgE (B) spleen weight.

image.png

Fig.4 OXA induced AD model in hIL4/hIL4R mice. (A) Pathology photos (B) Pathology score.

DNFB诱导的hIL4/hIL4R人源化小鼠AD模型及药效评价

image.png

Fig.1 Body weight of hIL4/hIL4Ra mice treated with dupilumab. *P<0.05.

image.png

Fig.2 Dupilumab ameliorate overall atopic dermatitis activity in DNFB-induced AD Model. *P<0.05, **P<0.01, ***P<0.001.

image.png

Fig.3 Dupilumab treatment significantly reduced IgE levels in serum and scratching times. (A) day10 serum IgE (B) day16 serum IgE (C) scratch times on Day 12 (D) scratch times on Day 14. *P<0.05, **P<0.01, ***P<0.001.

image.png

Fig.4 Dupilumab significantly mitigates inflammatory cell infiltration in lesioned skin on day 14. (A) dorsal image on day14; (B) Representative pathology images; (C) Inflammatory cell infiltration score; (D) neutrophils score; (E) eosinophils score; (F) epidermis thickness; (G) dermis thickness. *P<0.05, **P<0.01, ***P<0.001.

微信咨询 qrcode 请拨打 400 728 0660 在线咨询 回到顶部